Richard A Furie
Overview
Explore the profile of Richard A Furie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary
Werth V, Furie R, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven R, et al.
Immunotherapy
. 2025 Feb;
:1-13.
PMID: 39995069
No abstract available.
2.
Furie R, van Vollenhoven R, Kalunian K, Navarra S, Romero-Diaz J, Werth V, et al.
Immunotherapy
. 2025 Feb;
:1-13.
PMID: 39995062
No abstract available.
3.
Morand E, van Vollenhoven R, Furie R, Kalunian K, Manzi S, Abreu G, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39948001
Objectives: To investigate the long-term impact of anifrolumab versus placebo on lupus low disease activity state (LLDAS) and definition of remission in systemic lupus erythematosus (DORIS) attainment in patients with...
4.
Furie R, Rovin B, Garg J, Santiago M, Aroca-Martinez G, Zuta Santillan A, et al.
N Engl J Med
. 2025 Feb;
PMID: 39927615
Background: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. Methods:...
5.
Aringer M, Arnaud L, Furie R, Morand E, Peschken C, Hoi A, et al.
Lupus Sci Med
. 2025 Jan;
12(1).
PMID: 39855677
Objectives: Systemic lupus erythematosus (SLE) is a disease with heterogeneous treatment patterns largely based on organ involvement and disease severity. The SLE Prospective Observational Cohort Study (SPOCS) collected data worldwide...
6.
Askanase A, Furie R, DallEra M, Bomback A, Schwarting A, Zhao M, et al.
Lupus Sci Med
. 2024 May;
11(1).
PMID: 38777595
Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was 'minimising disease activity with the fewest treatment-associated toxicities and slowing or preventing organ damage progression'. The...
7.
Baker T, Sharifian H, Newcombe P, Gavin P, Lazarus M, Ramaswamy M, et al.
Ann Rheum Dis
. 2024 Apr;
83(8):1018-1027.
PMID: 38569851
Introduction: Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab...
8.
McDonnell S, Nguyen V, Walton N, Merkwirth C, Hong F, Berg D, et al.
Lupus Sci Med
. 2024 Mar;
11(1).
PMID: 38453421
Objective: To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE). Methods: A phase 1b double-blind,...
9.
Strand V, OQuinn S, Furie R, Morand E, Kalunian K, Schwetje E, et al.
Lancet Rheumatol
. 2024 Jan;
4(3):e198-e207.
PMID: 38288936
Background: The British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) is a validated global measure of treatment response in systemic lupus erythematosus (SLE) clinical trials but does not include...
10.
Morand E, Furie R, Bruce I, Vital E, DallEra M, Maho E, et al.
Lancet Rheumatol
. 2024 Jan;
4(4):e282-e292.
PMID: 38288923
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by multisystem involvement. We aimed to evaluate the efficacy of anifrolumab on organ domain-specific SLE disease activity. Methods: In...